All through October, CURE highlighted analysis developments and evolving remedy methods that proceed to form most cancers care. From minimally invasive surgical advances to rising drug combos, this month’s protection underscored the significance of innovation and shared data.
The next tales replicate significant progress and the voices of people instantly impacted.
In an
He defined that laparoscopic and robotic “keyhole” surgical procedures allow tumor removing via small incisions utilizing specialised devices and a telescopic digicam. Using three-dimensional anatomical fashions generated from sufferers’ computed tomography (CT) or magnetic resonance imaging (MRI) scans has additional enhanced surgical planning. These fashions permit surgeons to raised perceive tumor depth and surrounding anatomy earlier than and throughout the process.
“Minimally invasive surgical procedure … allowed us to supply nearly all of our sufferers a partial nephrectomy. Partial nephrectomy means eradicating simply the a part of the kidney and preserving the remainder of the kidney in order that sufferers can have a greater high quality of life and reduce their threat of needing dialysis sooner or later,” Munver said to CURE.
Outcomes from the part 3 FRUSICA-2 research instructed that combining Fruzaqla (fruquintinib) with Tyvyt (sintilimab) could present a promising new remedy possibility for sufferers with superior renal cell carcinoma (RCC) whose illness progressed after first-line remedy.
On this randomized, open-label trial, 234 sufferers obtained both the Fruzaqla and Tyvyt mixture or monotherapy with Inlyta (axitinib) or Afinitor (everolimus). Median progression-free survival (PFS) was 22.2 months with the mix versus 6.9 months with monotherapies. The target response fee additionally favored the mix at 60.5% in contrast with 24.3%.
Investigators reported that the security profile aligned with what is predicted from every particular person agent. Though grade 3 (extreme) or increased unintended effects had been extra frequent within the mixture group, the marked enchancment in illness management and length of response indicated significant scientific profit. Regulatory overview for the mix remedy is now underway in China.
Fran Curtis, a five-time most cancers survivor, spoke with CURE concerning her expertise navigating a bladder most cancers analysis in 2016. Though she beforehand survived breast, appendix and pores and skin cancers, she described bladder most cancers as essentially the most emotionally difficult because of considerations concerning doable removing of the bladder and concern of recurrence.
Curtis emphasised that her earliest signs had been delicate urinary adjustments quite than seen blood within the urine. She inspired girls to hunt well timed analysis for any persistent urinary signs, noting that early detection can considerably increase remedy choices.
“I am 1762451264 cancer-free, and I’ve had a number of checkups. Despite the fact that the therapies are scary, if it does not work, there’s different choices as nicely. There’s all the time hope,” she emphasised to CURE.
Curtis went on to credit score robust help from household and her care staff for sustaining her via remedy. Her message to others: persistence and hope stay important, as new therapies proceed to emerge.
Invoice Parisi participated within the
“If it helps any individual or it’s instructing these folks, then that’s what it’s all about,” he emphasised within the interview.
Parisi inspired sufferers to ask questions, search second opinions and take into account scientific trials as a part of their care discussions. He additionally highlighted the important position of compassionate, accessible medical groups in serving to sufferers really feel supported and knowledgeable.
CURE explains the which means of a stage 2 prostate adenocarcinoma analysis, together with how tumor measurement, prostate-specific antigen (PSA) ranges and Gleason-based grade group affect each staging and remedy planning.
As a result of stage 2 prostate most cancers stays localized to the prostate, the prognosis is usually wonderful. Remedy choices could embrace radical prostatectomy, exterior beam radiation remedy (EBRT), brachytherapy, or lively surveillance relying on age, total well being, and illness traits. Clear communication with an oncology staff stays central to creating a remedy alternative aligned with private priorities.
References
- “Minimally Invasive Kidney Most cancers Therapies Boosts Affected person Restoration,” by Dr. Ravi Munver. CURE; Oct. 9, 2025. https://www.curetoday.com/view/minimally-invasive-kidney-cancer-treatments-boosts-patient-recovery
- “Fruzaqla and Tyvyt Combo Exhibits Improved Outcomes in Superior Kidney Most cancers,” by Ryan Scott. CURE; Oct. 14, 2025. https://www.curetoday.com/view/fruzaqla-and-tyvyt-combo-shows-improved-outcomes-in-advanced-kidney-cancer
- “5-Time Survivor Displays on Bladder Most cancers: ‘There’s At all times Hope’,” by Alex Biese. CURE; Oct. 22, 2025. https://www.curetoday.com/view/five-time-survivor-reflects-on-bladder-cancer-there-s-always-hope-
- “SUNRiSE-1 Participant Shares Insights on Bladder Most cancers Schooling,” by Ryan Scott. CURE; Nov. 1, 2025. https://www.curetoday.com/view/sunrise-1-participant-shares-insights-on-bladder-cancer-education
- “FDA Approves Inlexzo for Some With Non–Muscle Invasive Bladder Most cancers,” by Alex Biese. CURE; Sept. 9, 2025. https://www.curetoday.com/view/fda-approves-inlexzo-for-some-with-non-muscle-invasive-bladder-cancer
- “What Does a Stage 2 Prostate Most cancers Analysis Imply for Me?,” by Gina Mauro. CURE. https://www.curetoday.com/view/what-does-a-stage-2-prostate-cancer-diagnosis-mean-for-me-
